TACSTD2 and breast carcinoma: It was found that Trop-2 is highly expressed in early-stage luminal-like breast cancer (94%) and that Trop-2 expression is not correlated with clinicopathological features such as patient age, histological subtype, pathological grade, Ki67, tumor size, lymph node status, or lymph node metastasis.